Objective: Sildenafil and apomorphine are oral agents for the improvement of erection hardness. The aim of the study was a direct comparison of the two compounds under clinical routine conditions.
Methods: 131 previously untreated men with erectile dysfunction (ED) were enrolled in a cross-over trial and randomly allocated to 50 mg sildenafil or 2 mg apomorphine. Dose-adaptation was allowed as required.
Results: Improvements in rigidity, the capacity to get and maintain an erection, and sexual confidence were statistically significantly larger with sildenafil (p <0.0001). 90% of the men were satisfied with sildenafil as compared to 46% with apomorphine. At study end, 95% of the patients preferred sildenafil. Both agents were well tolerated.
Conclusions: In this cross-over comparison under clinical routine conditions men reported superior efficacy of sildenafil vs apomorphine together with a statistically significantly higher treatment satisfaction.
Download full-text PDF |
Source |
---|
RSC Adv
January 2020
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University Egypt.
By 2025, it's estimated that 322 million males worldwide will suffer from sexual disorders. This can give an estimation for the size of the pharmaceutical and counterfeit products industry for the next few years. Meanwhile, green analytical chemistry forced itself to decrease the massive environmental pollution and hence new analytical methodologies are needed to replace the old ones that consume large amounts of hazardous solvents.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
January 2020
Russian Medical Academy for Continuing Professional Education, Moscow, Russia.
Erectile dysfunction (ED) significantly deteriorates the quality of life of patients with Parkinson's disease (PD). Until recently, treatment of ED received insufficient attention. Management of ED in patients with PD requires an integrated and multidisciplinary approach.
View Article and Find Full Text PDFBasic Clin Pharmacol Toxicol
October 2016
Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus C, Denmark.
The currently recommended first-line treatments of erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i), for example sildenafil, are efficacious in many patients with ED of vascular origin, but this therapy is insufficient in approximately 30-40% of men with ED where there is also a neuronal affection. There is a demand of novel approaches to treat the condition. We review the possibility of modulating the dopaminergic pathways to improve erectile function.
View Article and Find Full Text PDFInt J Reprod Biomed
February 2016
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background: Lithium has been the treatment of choice for bipolar disorder (BD) for many years. Although erectile dysfunction is a known adverse effect of this drug, the mechanism of action by which lithium affects erectile function is still unknown.
Objective: The aim was to investigate the possible involvement of nitric oxide (NO) in modulatory effect of lithium on penile erection (PE).
Objective: To investigate the effect of Bushengzhuyang Fang (Yangjing Capsule, YJC) on penile erectile function and its action mechanisms in rats.
Methods: Fifty-six male SD rats were randomly divided into seven groups of equal number: blank control, daidzein, daidzein + testosterone, daidzein + sildenafil, daidzein + low-dose YJC, daidzein + medium-dose YJC, and daidzein + high-dose YJC. The rats in the blank control group were treated intragastrically with normal saline and those in the other groups with daidzein at the dose of 100 mg per kg per day for 30 days.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!